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1018 The Journal of Thoracic and CardObjectives: This study retrospectively reviews an aggressive multidisciplinary ap-
proach to the treatment of massive pulmonary embolism, centering on rapid diag-
nosis with contrast-enhanced computed tomography of the chest to define the
location and degree of clot burden and transthoracic echocardiography to document
right ventricular strain followed by immediate surgical intervention when appropri-
ate.
Methods: Between October 1999 through February 2004, 47 patients (30 men and
17 women; median age, 58 years; age range, 24-86 years) underwent emergency
surgical embolectomy for massive central pulmonary embolism. The indications for
surgical intervention were (1) contraindications to thrombolysis (21/47 [45%]), (2)
failed medical treatment (5/47 [10%]), and (3) right ventricular dysfunction (15/47
[32%]). Preoperatively, 12 (26%) of 47 patients were in cardiogenic shock, and 6
(11%) of 47 were in cardiac arrest.
Results: There were 3 (6%) operative deaths, 2 with preoperative cardiac arrest; 2
of these 3 patients required a right ventricular assist device. In 38 (81%) patients a
caval filter was placed intraoperatively. Median length of stay was 11 days (range,
3-75 days). Median follow-up was 27 months (range, 2-50 months); follow-up was
100% complete in surviving patients. There were 6 (12%) late deaths, 5 of which
were from metastatic cancer. Actuarial survival at 1 and 3 years’ follow-up was 86%
and 83%, respectively.
Conclusion: An aggressive approach to large pulmonary embolus, including rapid
diagnosis and prompt surgical intervention, has improved results with surgical
embolectomy. We now perform surgical pulmonary embolectomy not only in
patients with large central clot burden and hemodynamic compromise but also in
hemodynamically stable patients with right ventricular dysfunction documented by
means of echocardiography.
Despite advances in diagnosis and therapy, acute pulmonary embolism (PE)is still associated with a high mortality rate. According to data published inthe International Cooperative Pulmonary Embolism Registry, 2454 patients
with acute PE from 52 hospitals in 7 countries died within 90 days.1 Most deaths
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therapy for PE is anticoagulation with heparin. Adjunctive
treatment options include thrombolysis, catheter embolec-
tomy, and surgical embolectomy. Thrombolysis has a rela-
tively high rate of intracranial bleeding (3% as reported by
the International Cooperative Pulmonary Embolism Regis-
try),1 and catheter embolectomy might not retrieve all of the
clot material.2
In the past, surgical pulmonary embolectomy has usually
been reserved for patients with massive PE who present in
cardiogenic shock. This approach is associated with high
mortality rates, ranging from 16% to 64%.3,4 In October
1999,5 we liberalized the indications of surgical embolec-
tomy for acute PE at our institution to include patients with
large anatomically extensive clot and moderate-to-severe
right ventricular dysfunction (RVD) without shock to im-
prove early and late survival in this condition.5 The ratio-
nale for this approach is based on numerous observations
that implicate RVD as an early and late risk factor for right
ventricular (RV) failure, RV ischemic infarction,6 and
death.7
Figure 1. Contrast-enhanced CT (axial section) showing large
TABLE 1. Risk factors for development of pulmonary em-





Prior pulmonary embolism 1 (2%)
Hypercoagulability 1 (2%)
Vascular anomaly 1 (2%)
Smoking history 1 (2%)
None 2 (4%)
DVT, Deep vein thrombosis.saddle embolus in the PA (black arrows).
The Journal of ThoracicOur multidisciplinary approach is based on rapid diag-
nosis with computed tomography (CT) and echocardiogra-
phy to identify patients with severe RVD and likely poor
early outcome.5,8 In this article we present our series of 47
consecutive patients who underwent surgical pulmonary
embolectomy over a 4-year period.
Methods
From October 1999 through February 2004, 47 patients underwent
surgical pulmonary embolectomy for treatment of acute PE. The
study included 30 (30/47 [64%]) men. Mean age was 59  14
years (median, 58 years; range, 24-86 years). Preoperative risk
factors for development of PE are presented in Table 1. The most
common presenting symptom was dyspnea (n  40, 85%) fol-
lowed by chest pain (n  15, 32%), hemodynamic instability (n 
12, 26%), syncope (n  6, 13%), and cardiac arrest (n  6, 13%).
Echocardiography was performed in 42 (89%) of 47 patients,
and moderate or severe RVD was present in 40 (95%) of 42
Figure 2. Transesophageal echocardiogram revealing RV strain
and bulging of the interatrial septum (arrowheads). RA, Right
atrium; LA, left atrium.
TABLE 2. Indications for surgical embolectomy (n  47)
Indication N (%)
Contraindications to thrombolysis 21 (45%)
Recent surgical intervention 10 (21%)
Active bleeding 3 (6%)
Stroke 4 (9%)
Other 4 (9%)
Failed medical treatment 5 (10%)
Failure of thrombolytics 4 (9%)
Failure of catheter embolectomy 1 (2%)
Large RA-RV thrombus 5 (10%)
RV hemodynamic dysfunction 15 (32%)
Large PFO 1 (2%)RA-RV, Right atrium–right ventricle; PFO, patent foramen ovale.
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RV/left ventricular end-diastolic diameter ratio of greater than 1 in
the apical 4-chamber view, (2) an RV end-diastolic diameter of
greater than 30 mm, or (3) paradoxical RV septal systolic motion.
Chest CT scans were performed in 41 (87%) of 47 patients
(Figure 2), and pulmonary angiography was performed in 5 (11%)
of 47 patients. In one patient no diagnostic studies were done
because the patient experienced cardiac arrest on arrival to the
operating room, where he was scheduled for delayed chest closure
after mitral valve repair. The diagnosis of PE was made intraop-
eratively.
Indications for surgical pulmonary embolectomy are sum-
marized in Table 2. At initial evaluation, hypotensive patients
were defined as those with a systolic blood pressure of less than
100 mm Hg, and normotensive patients were defined as those
with a systolic blood pressure of greater than 100 mm Hg.
Patients in shock were so designated if they presented with
symptoms of hypoperfusion (ie, oliguria, cold and clammy skin,
and lactic acidosis) or were in cardiac arrest. Two groups of
patients were identified on the basis of echocardiographic ex-
amination and clinical status: normotensive patients with RVD
(n  15) and hypotensive patients with RVD (n  28). In the
group of patients who were hemodynamically unstable, 21 were
not eligible for thrombolysis and received medical treatment.
Five patients treated medically had hemodynamic deterioration
despite treatment.
Surgical Technique
Transesophageal echocardiography was performed in all patients
to assess the intracardiac structures for patent foramen ovale or
atrial septal defect, which, if found, would lead to changes in
cannulation and myocardial protection strategies. Epicardial echo-
cardiography was also used in some cases to determine the loca-
tion of intracardiac thrombi and identify direct cannulation sites.
After median sternotomy, the patients were heparinized and can-
Figure 3. Kaplan-Meier survival curve after surgical pulmonary
embolectomy (n  47 patients, including the 3 operative deaths).nulated for cardiopulmonary bypass (CPB). The operation was
1020 The Journal of Thoracic and Cardiovascular Surgery ● Maperformed under normothermic conditions without cardioplegic
arrest unless repair of a patent foramen ovale or atrial septal defect
was required. A longitudinal arteriotomy of the main pulmonary
artery (PA) trunk was performed, and if necessary, an additional
arteriotomy of the right PA between the ascending aorta and the
superior vena cava was made. Alternatively, a transverse arteriot-
omy in the distal main PA extending onto the left or right PA was
carried out. Clots were removed under direct vision by using
gallbladder stone forceps and suction. Fogarty catheter clot extrac-
tion was avoided to reduce the possibility of injury to the PA
branches. Temporary reductions in CPB flow were occasionally
needed to permit better clot visualization. After weaning from
CPB, an inferior vena caval filter was inserted in most cases
through the right atrial purse string.
Statistical Analysis
The data are expressed as means  SD or percentages. Long-term
survival rates were calculated by using the Kaplan-Meier method.
We used the STATA 7.0 for Windows (STATA, College Station,
Tex) statistical software package.
Results
We observed the following distribution of emboli with
respect to the pulmonary arteries: bilateral PAs and main
trunk in 39 (83%) of 47 patients, left PA only in 2 (4%) of
47 patients, and right PA only in 6 (13%) of 47 patients.
Inferior vena caval filters were inserted in 38 (81%) of 47
patients. Thirty-six patients received the filter after surgical
embolectomy, and 2 received the filter preoperatively.
Three (6%) patients died within 30 days of the operation.
A 50-year-old man died on postoperative day 19 after
recurrent PE and severe RV failure and before we adopted
the routine use of caval filters. Reoperative embolectomy
with RV assist device placement was not successful. A
34-year-old man who previously underwent knee arthros-
copy presented in cardiac arrest. He did recover hemody-
namically after pulmonary embolectomy but never regained
consciousness and was declared brain dead on the second
postoperative day. The third patient was an 84-year-old
woman who presented for embolectomy with worsening
hypoxia after thrombolytic treatment failure. She experi-
enced aortic dissection during cannulation and died as a
result of intractable bleeding after aortic repair.
Two (4%) patients had reoperations for mediastinal
bleeding, and 2 (4%) had deep sternal wound infections. An
RV assist device was implanted in 2 (4%) patients, one of
whom was successfully weaned.
Median follow-up was 27 months (range, 2-50 months),
and follow-up was 100% complete in 44 surviving patients.
There were 6 (12%) late deaths. Actuarial survival at 1 and
3 years’ follow-up was 86%  5% (CI, 0.70-0.90) at 1 year
and 83%  6% (CI, 0.66-0.92) at 3 years, respectively
(Figure 3). Five of the 6 patients with late deaths were given
diagnoses of cancer at the time of surgical embolectomy.
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The principal finding of this report is that use of expanded
indications for pulmonary embolectomy was associated
with a reduced operative risk. We considered embolectomy
not only in patients with traditional indications, such as
failed medical therapy, but also in hemodynamically stable
patients with large central clot burden and documented
RVD. A multidisciplinary approach, with 24-7 availability,
rapid precise diagnosis, and rapid transfer to the operating
room, is the key to our management strategy. Spiral CT
offers rapid imaging acquisition and direct visualization of
emboli within the pulmonary arteries and subsegmental
vessels.9 The widespread availability of chest CT scanning
renders this the preferred diagnostic tool for rapid and
noninvasive detection of large central clot and superior to
the classical contrast pulmonary angiography, which can
cause hypotension. Cardiac biomarkers, such as troponin
and brain natriuretic peptide increase, can identify patients
with PE who are likely to do poorly on anticoagulation
therapy alone.10
Thrombolytic treatment offers a more rapid rate of
resolution of pulmonary emboli than the standard treat-
ment with heparin alone and is indicated in patients with
massive PE. There are, however, few studies focusing
on the long-term outcome of patients who receive throm-
bolysis treatment and no data comparing surgical and
medical treatment in patients eligible for both treat-
ments.11-13
Catheter embolectomy as a therapeutic modality can be
performed during contrast pulmonary angiography. How-
ever, commercially available catheters tend to fragment the
embolus rather than extracting it,2 causing the embolus
particles to propagate further into the pulmonary circula-
tion, thus placing patients at risk for subsequent pulmonary
hypertension.
Identification of a central surgically accessible PE
(within the main trunk or left or right main PA) is required
before considering surgical therapy. The best surgical can-
didates are those patients with a large amount of clot limited
to the central main branches. Patients with most of their clot
burden located peripherally do not do well with surgical
intervention. Patients with central clotting that extends pe-
ripherally do well with surgical intervention, but the sur-
geon must be prepared to systemically cool on CPB to
permit modulation of CPB flows for better visualization
during clot removal.
We have extended the indications for surgical interven-
tion beyond the traditional indications for massive PE (ie,
failure of lytic treatment or hemodynamic compromise) to
include hemodynamically stable patients with massive cen-
tral clot burden and signs of RVD on echocardiogram. The
latter represents a controversial group.11,12 Our approach
was recently replicated by Yalamanchili and colleagues,14
The Journal of Thoracicwith 8% mortality. Development of shock and multisystem
organ failure as a consequence of RV failure is associated
with at least 30% mortality, whereas if cardiac arrest occurs,
mortality approaches 70%.7
A decrease of mortality in surgical PE series from 57%
in the 1960s15 to 26% in the 1990s16 to 6% in our series has
been documented. In the past, pulmonary embolectomy was
the treatment of last resort for patients with PE because it
was associated with high mortality. The average morbidity
from different series between 1982 and 1999 is about
30%.14 This approach has changed over time. Increasingly
more often, centers are reporting PE as an integral part of
their treatment algorithm for patients with both massive and
submassive PE, where massive PE is defined as the presence
of persistent systemic hypotension or cardiogenic shock and
signs of RVD, and submassive PE is defined as moderate-
to-large clot, presence of RVD, and normal arterial blood
pressure.17
Very few studies have compared medical versus surgical
treatment for PE. In a nonrandomized comparison of surgi-
cal and medical treatment in hemodynamically compro-
mised patients with massive PE, the medical group had an
increased mortality rate, increased number of hemorrhagic
events, and a higher rate of recurrent PE.18
Significantly higher mortality rates are observed in
patients who undergo cardiopulmonary resuscitation
(CPR).7 Furthermore, patients brought to the operating
room undergoing continuous CPR have a higher mortal-
ity than those undergoing intermittent CPR with stable
hemodynamics on arrival to the operating room (80% vs
40%, respectively).19 We experienced similar findings
with our cohort. Six patients had cardiac arrest and
required CPR, of whom 2 died. One patient had recurrent
PE in the hospital and experienced a cardiac arrest. The
other patient was transferred from an outside hospital
under continuous CPR, which continued until the opera-
tion, and spontaneous rhythm was never established pre-
operatively. These results raise questions about the ap-
propriateness of aggressive surgical therapy with out-of-
hospital cardiac arrest and prolonged unsuccessful CPR.
RVD without shock is a controversial, but we believe
reasonable, indication for surgical embolectomy, because
as PA-RV pressures increase, the right ventricle might
ultimately fail. RV ischemia caused by interatrial septum
displacement might reduce coronary artery perfusion to
the right ventricle, which can cause RV ischemic infarc-
tion and death.6,7
Another controversial issue centers around the perioper-
ative placement of a vena caval filter. The recurrence rate of
PE after surgical pulmonary embolectomy is as high as 5%.3
In a randomized trial assessing use of inferior vena caval
filter placement versus no filter in patients with proximal
deep-vein thrombosis, there were no differences in early or
and Cardiovascular Surgery ● Volume 129, Number 5 1021
Surgery for Acquired Cardiovascular Disease Leacche et al
A
CDlate mortality.20 However, the same study revealed the
initial efficacy of filters for the prevention of PE in the first
year. Because one of our first patients experienced a fatal
recurrent PE, we now always place a vena caval filter at the
time of surgical pulmonary embolectomy.
Limitations
The retrospective nature of our study is the main limitation.
A prospective randomized trial of medical versus surgical
treatment would be optimal.
Conclusion
In this report we document that surgical pulmonary embo-
lectomy can be performed with low perioperative mortality
and good midterm survival. Factors important to achieving
a good result include a multidisciplinary approach with
rapid noninvasive diagnostics, proper risk stratification, and
availability of immediate surgical treatment. Thus we now
offer surgical pulmonary embolectomy not only to patients
with large central clot burden and severe hemodynamic
compromise but also to hemodynamically stable patients
with RVD documented by means of echocardiography.
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Discussion
Dr Kwok Yun (Los Angeles, Calif). The current study is a con-
tinuation of an initial series of 29 patients that was initially
published in Circulation in March of 2002. From this study, the
authors conclude that in addition to the traditional indications of
hemodynamic instability or failure of medical management, sur-
gical intervention should be extended to stable patients with signs
of impending RVD and failure on the basis of echocardiography.
What stands out in this report is not so much indisputable evidence
that pulmonary embolectomy should be performed in this latter
group of patients but rather the impressive success with those who
were unstable and presented in cardiac arrest. This leads to my first
question. According to the initial report, one of the lessons learned
from the first 29 patients was that cardiac arrest was a relative
contraindication to emergency surgical intervention. Yet 5 of the
next 18 patients in the series had cardiac arrest. Has the philosophy
regarding these high-risk patients changed in your institution, and
if so, why?
Dr Byrne. It is all individualized. In an elderly person with
comorbidities, we probably would not want to do the operation.
All we have are the ones whom we operated on, so the ones who
did have cardiac arrest, I think 6 of the 47, were typically young,
otherwise healthy people who were previously healthy and had
CPR. Now we appreciate that getting someone back is a tough
problem because they do not oxygenate their blood very well, and
they could end up brain dead. In fact, 2 of the 6 patients did die
here, and therefore there was a 33% operative mortality instead of
6% overall. I agree it is a controversial area, but it is all individ-
ualized. For a young, otherwise healthy person, I think you should
give that person a shot.
Dr Yun. Although only 3 patients died within 30 days of
operations, according to your article, another patient could not be
weaned from RV assist device, giving a hospital mortality of 8.5%.
How many of the 5 late deaths were actually in-hospital deaths
beyond the 30-day period?
Dr Byrne. The RV assist device was weaned in that patient. It
was able to be weaned, but your question is how many out beyond
30 days? Well, we have the late, 2-year follow-up. We have 100%
follow-up out to a median of 2 years, and there were 6 late deaths;
5 of 6 had cancers.
Dr Yun. Regarding the subset of 15 patients with preserved
arterial pressure but significant RVD, did the decision to operate
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stratification scheme, such as the Geneva Prognostic Index, or
additionally guided by the use of biomarkers, such as troponin and
B-type natriuretic peptides?
Dr Byrne. That is a good question. We did not use any of the
biomarkers. In the patients on whom we operated, all were symp-
tomatic. About a third were hemodynamically stable, but their sole
indication other than symptoms was impending RV failure, as
documented by those echocardiograms that showed massively
dilated dysfunctional RV. We do not have data on how many
patients in whom we said, okay, their right ventricle is not that bad,
let’s hold off, but that is something that we need to do.
Dr Yun. To be the devil’s advocate, in the Management
Strategy and Prognosis of Pulmonary Embolism 3 trial comparing
thrombolysis plus heparin with heparin alone in stable patients, the
overall mortality was 2.7%, without significant differences be-
tween the 2 treatment arms. Unfortunately, the report does not
specify the mortality rate of patients with impending hemody-
namic instability because of RVD, which constituted about 30% of
the cases, the same as in your series, which was about 32%. However,
even if one assumes that all deaths occur in this subset of patients, the
worst-case mortality would still be at a respectable 8.5%. Compared
with the 6.5% in this series, what is the rationale for operation in the
stable patient with RVD without some sort of a randomized trial
unless there is a contraindication to thrombolysis?
Dr Byrne. That is a really good question. I think it comes down
to a multidisciplinary approach that many cardiologists have
bought into because they believe the operation is very effective
and safe. I think it is just going to take some education, debate, and
eventually a randomized trial to figure this one out. To be able to
stratify RVD, we all need that denominator that we talked about
before—the people with RVD but who did not undergo an oper-
ation—and see what their outcome was.
Dr Scott Mitchell (Stanford, Calif). We have a very aggressive
group of interventionalists at Stanford, and therefore if we see
these patients in the condition in which they are still clinically
stable but have a contraindication to heparin or systemic throm-
bolysis, then we undergo regional thrombolysis with some of these
mechanical devices. This seems like the perfect milieu when the
patients are still stable. My question is, do you have experience
The Journal of Thoracicwith those devices, and do you have the same aggressive inter-
ventionalists?
Dr Byrne. I think the answer is because we do not have the
same aggressive interventionalists, we do not have that treatment
arm at our hospital.
Dr John Chen (Honolulu, Hawaii). This is a very sick group
of patients, and that is a quite an achievement to save their lives.
We do not have a CAT scanner at the door, and therefore my
question is as follows: Did you, in the course of your study, find
any particular factors that would predict who these patients are?
Dr Byrne. There is a whole body of literature looking at people
at risk for PE. If someone showed up with shortness of breath with
or without chest pain who did not have other obvious causes, they
got run through the CAT scan pretty quickly. There is a low
threshold to consider it. It all has to do with thinking of the
diagnosis and considering it and running them through the CAT
scan.
Dr Chen. It sounds like at the Brigham they do not do a history
and physical examination anymore. The CAT scan is the study of
choice?
Dr Byrne. Well, you know, that emergency department. I try to
go down there as little as possible because they might run me
through the CAT scan. (laughter)
Dr Thor Sundt (Rochester, Minn). This is probably as much a
comment as a question. Could you detail for us your technical
approach to the right PA? I have found it particularly helpful to
open the right PA behind the aorta, as one does for pulmonary
thromboendarterectomy, and have taught the residents to do just
that. I just wanted to highlight that technical point, which we
believe is important to enable complete extraction of thrombus. I
prefer this rather than trying to reach around a right-angle corner
with a stone forceps from an incision in the main PA. Is this your
practice?
Dr Byrne. Any time there is clot on the right side, we do that
maneuver. It takes just a few minutes. I find it helpful, by the way,
to stand on the left side of the table for these cases. I put on a head
light, and I can see down that right PA beautifully. The left PA is
of course going straight down, and you can see there, but the right
PA would be very hard to—you would be putting your head in the
field to try to look down the right PA, but from the left side of the
table you can see it really well.
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